Daily Ards Research Analysis
A nationwide population-based analysis redefines the learning-curve threshold for robot-assisted lung cancer surgery and links inadequate experience to higher rates of severe complications, including ARDS. A very large trauma cohort identifies whole blood transfusion as a small but significant risk factor for developing ARDS, while fresh frozen plasma shows no association. Maternal-fetal miRNA signals in placenta accreta spectrum correlate with neonatal respiratory morbidity and the timing of an
Summary
A nationwide population-based analysis redefines the learning-curve threshold for robot-assisted lung cancer surgery and links inadequate experience to higher rates of severe complications, including ARDS. A very large trauma cohort identifies whole blood transfusion as a small but significant risk factor for developing ARDS, while fresh frozen plasma shows no association. Maternal-fetal miRNA signals in placenta accreta spectrum correlate with neonatal respiratory morbidity and the timing of antenatal corticosteroids.
Research Themes
- Transfusion practices and ARDS risk
- Surgical learning curves and severe respiratory complications
- Maternal-fetal biomarkers and neonatal respiratory morbidity
Selected Articles
1. Evaluation of the Learning Curve Threshold in Robot-Assisted Lung Cancer Surgery: A Nationwide Population-Based Study.
This nationwide analysis shows that hospitals typically need around 110 robot-assisted lung cancer surgeries (range 94–174) to reach a learning curve associated with fewer severe complications. Institutions not reaching this threshold had significantly higher rates of severe events including acute respiratory distress syndrome, challenging the commonly cited 25-procedure benchmark.
Impact: Redefining learning-curve thresholds has immediate implications for credentialing, centralization, and patient safety, including ARDS prevention. The nationwide scope and methodologically robust approach increase its policy and practice relevance.
Clinical Implications: Hospitals should reconsider minimum case volumes before independently offering robot-assisted lung cancer surgery and implement quality monitoring to mitigate severe complications, including ARDS. Credentialing standards may need to be raised to approximately 100–170 cases.
Key Findings
- Learning-curve thresholds ranged from 94 to 174 procedures (median 110), not 25.
- Severe complications, including ARDS, were significantly more frequent in hospitals that did not validate the threshold.
- Robotic procedures increased from 195 (2019) to 1567 (2022), totaling 3706 surgeries.
- 24.7% of patients experienced Clavien-Dindo > II postoperative complications.
Methodological Strengths
- Nationwide medico-administrative dataset with comprehensive coverage
- Use of a composite quality indicator and sequential probability ratio test
- Clear, clinically relevant endpoints including severe complications
Limitations
- Observational design with potential residual confounding
- Reliance on administrative coding (misclassification risk)
- Generalizability may be limited outside France
Future Directions: Prospective evaluation of training and credentialing thresholds, linkage with patient-level clinical data, and external validation in other healthcare systems.
BACKGROUND: Recent publications suggest that the threshold for validation of the learning curve is 25 procedures. The aim of this study was to evaluate this threshold using another rarely used method, based on a composite quality indicator. METHODS: We included all patients from the French medico-administrative database receiving robot-assisted surgery for lung cancer, with a focus on hospitals performing at least 25 procedures over the period 2019-2022. For postoperative complication analysis, we used the Clavien-Dindo classification. We used the sequential probability ratio test to estimate the number of procedures at which a hospital achieved its learning curve. RESULTS: In France, the number of robotic-assisted procedures has risen steadily in the past few years: 195 in 2019 and 1567 in 2022 (overall, 3706 Robot-Assisted surgeries). The total number of patients with Clavien-Dindo classification > II was 833 (24.7%). Among the 28 hospitals performing at least 25 procedures, eight achieved their learning curve with thresholds ranging from 94 to 174 procedures, and the median was 110. Severe complications such as acute respiratory distress syndrome, respiratory failure, heart failure, acute ischemia of the lower limbs, or pulmonary embolism were significantly more frequent in the group of hospitals that did not validate the learning curve threshold. CONCLUSIONS: This study suggests that the threshold of 25 procedures may not be sufficient to validate the robot-assisted surgery learning curve in lung cancer surgery. To significantly reduce postoperative complications, a hospital would need to perform 94 to 174 procedures to guarantee patient safety.
2. An Analysis of the Association of Whole Blood Transfusion With the Development of Acute Respiratory Distress Syndrome.
In a retrospective cohort of 134,863 trauma patients receiving blood products, whole blood transfusion was associated with increased odds of developing ARDS (uOR 1.05; 95% CI 1.02–1.07). Male sex, higher shock index, and higher injury severity were also associated, while fresh frozen plasma showed no association.
Impact: This very large analysis clarifies transfusion-related ARDS risk in modern trauma care and challenges assumptions about plasma. It can inform protocol design and risk stratification pending prospective confirmation.
Clinical Implications: Trauma teams should weigh the small but measurable ARDS risk when using whole blood and enhance monitoring of high-risk recipients. Transfusion protocols may prioritize individualized product selection while prospective trials assess causality.
Key Findings
- Whole blood transfusion increased odds of ARDS (unit OR 1.05; 95% CI 1.02–1.07).
- Male sex, higher arrival shock index, and higher Injury Severity Score were associated with ARDS.
- ARDS incidence was 1% and associated with lower discharge survival (61% vs 74%).
- No association between fresh frozen plasma administration and ARDS was found.
Methodological Strengths
- Very large sample size from a national trauma registry (TQIP)
- Multivariable modeling with sensitivity analyses
- Clinically relevant outcomes and granular injury severity measures
Limitations
- Retrospective design with potential residual confounding
- ARDS diagnosis based on registry/administrative coding
- Possible selection and indication biases in transfusion practices
Future Directions: Prospective studies or pragmatic trials comparing transfusion strategies (including whole blood) with ARDS as a pre-specified outcome; refinement of risk prediction incorporating physiologic data.
OBJECTIVES: To determine the association of whole blood and other blood products (components, prothrombin complex concentrate, and fibrinogen concentrate) with the development of acute respiratory distress syndrome (ARDS) among blood recipients. DESIGN: Retrospective cohort study. SETTING: American College of Surgeons Trauma Quality Improvement Program (TQIP) database between 2020 and 2021. PATIENTS: Patients 15 years old or older in the TQIP database between 2020 and 2022 who received at least one blood product. INTERVENTIONS: We compared characteristics and blood product administration between patients who developed ARDS versus those who did not. MEASUREMENTS AND MAIN RESULTS: There were 134,863 that met inclusion for this analysis. Within the included population, 1% (1927) was diagnosed with ARDS. The no ARDS group had a lower portion of serious injuries to the head/neck (31% vs. 46%), thorax (51% vs. 78%), abdomen (34% vs. 48%), and extremities (37% vs. 47%). The median composite Injury Severity Score was 21 (11-30) in the no ARDS group vs. 30 (22-41) in the ARDS group. Unadjusted survival of discharge was 74% in the no ARDS group vs. 61% in the ARDS group. In our multivariable model, we found that whole blood (unit odds ratio [uOR], 1.05; 95% CI, 1.02-1.07), male sex (odds ratio, 1.44; 95% CI, 1.28-1.63), arrival shock index (uOR, 1.03; 95% CI, 1.01-1.06), and composite Injury Severity Score (uOR, 1.03; 95% CI, 1.03-1.04) were associated with the development of ARDS. These persisted on sensitivity testing. CONCLUSIONS: We found an association between whole blood and the development of ARDS among trauma patients who received blood transfusions. Contrary to previous studies, we found no association between ARDS and fresh frozen plasma administration. The literature would benefit from further investigation via prospective study designs.
3. Increased Levels of hsa-miR-199a-3p and hsa-miR-382-5p in Maternal and Neonatal Blood Plasma in the Case of Placenta Accreta Spectrum.
In 160 maternal-neonatal plasma samples, PAS was associated with elevated neonatal hsa-miR-199a-3p and hsa-miR-382-5p levels. When antenatal corticosteroids were administered within 14 days before delivery, these miRNA levels trended toward normalization, suggesting a molecular link between PAS, steroid timing, and neonatal respiratory morbidity.
Impact: Identifying PAS-associated miRNAs that respond to steroid timing provides a potential biomarker path to personalize antenatal therapy and anticipate neonatal respiratory risk.
Clinical Implications: For pregnancies complicated by PAS, timing antenatal corticosteroids within 14 days of delivery may confer respiratory benefit detectable at the molecular level; miR-199a-3p/miR-382-5p could be explored as response/risk markers.
Key Findings
- Neonates born to mothers with PAS had significantly higher plasma hsa-miR-199a-3p and hsa-miR-382-5p levels versus controls.
- Antenatal corticosteroids given within 14 days before delivery were associated with a trend toward normalization of these miRNAs.
- A direct correlation was observed between neonatal plasma hsa-miR-382-5p and hsa-miR-199a-3p levels (r = 0.49).
Methodological Strengths
- Use of small RNA deep sequencing with qRT-PCR validation
- Paired maternal-neonatal sampling enabling maternal-fetal linkage
- Defined gestational-age window (33–36 weeks) to reduce heterogeneity
Limitations
- Observational design limits causal inference regarding steroid effects
- Abstract truncation leaves some details (e.g., effect sizes) unclear
- Generalizability may be limited to late-preterm PAS populations
Future Directions: Prospective studies validating miR-199a-3p/miR-382-5p as biomarkers for neonatal respiratory outcomes in PAS and testing optimized steroid timing protocols.
Despite the increasing number of placenta accreta spectrum (PAS) cases in recent years, its impact on neonatal outcomes and respiratory morbidity, as well as the underlying pathogenetic mechanism, has not yet been extensively studied. Moreover, no study has yet demonstrated the effectiveness of antenatal corticosteroid therapy (CT) for the prevention of respiratory distress syndrome (RDS) in newborns of mothers with PAS at the molecular level. In this regard, microRNA (miRNA) profiling by small RNA deep sequencing and quantitative real-time PCR was performed on 160 blood plasma samples from preterm infants (gestational age: 33-36 weeks) and their mothers who had been diagnosed with or without PAS depending on the timing of the antenatal RDS prophylaxis. A significant increase in hsa-miR-199a-3p and hsa-miR-382-5p levels was observed in the blood plasma of the newborns from mothers with PAS compared to the control group. A clear trend toward the normalization of hsa-miR-199a-3p and hsa-miR-382-5p levels in the neonatal blood plasma of the PAS groups was observed when CT was administered within 14 days before delivery, but not beyond 14 days. Direct correlations were found among the hsa-miR-382-5p level in neonatal blood plasma and the hsa-miR-199a-3p level in the same sample (r = 0.49;